Overview

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Hizentra is a safe and effective treatment for people with myasthenia gravis (MG).
Phase:
Phase 2
Details
Lead Sponsor:
Mazen Dimachkie, MD
Collaborator:
CSL Behring
Treatments:
Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin